Últimas noticias sobre Guardforce AI Co (NASDAQ:GFAI) Bolsa

Guardforce AI Co

Guardforce AI Co Ltd is a provider of cash solutions and cash handling services located in Thailand. The company engages in the cash logistics business, and its services include cash-in-transit, or CIT, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions (cash deposit management and express cash service). Its customers include local commercial banks, chain retailers, coin-manufacturing mints, and government authorities.

Guardforce AI Co., Limited - Ordinary Shares

Guardforce AI Co Ltd

Wolfe Research analyst Alexandria Hammond initiates coverage on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Peer Perform rating.

News

Initiation

Analyst Ratings

Wolfe Research Initiates Coverage On Bristol-Myers Squibb with Peer Perform Rating

Wolfe Research analyst Tim Anderson initiates coverage on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Peer Perform rating.

AMGN

Wolfe Research Initiates Coverage On Amgen with Peer Perform Rating

Wolfe Research analyst Akash Tewari initiates coverage on Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform rating and announces Price Target of $95.

Price Target

BMRN

Wolfe Research Initiates Coverage On Biomarin Pharmaceutical with Outperform Rating, Announces Price Target of $95

Wolfe Research analyst Alexandria Hammond initiates coverage on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Peer Perform rating.

BIIB

Wolfe Research Initiates Coverage On Biogen with Peer Perform Rating

Wolfe Research analyst Alexandria Hammond initiates coverage on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Outperform rating and announces Price Target of $205.

ABBV

Wolfe Research Initiates Coverage On AbbVie with Outperform Rating, Announces Price Target of $205

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $135 price target.

Reiteration

BPMC

Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $23 price target.

CELC

Needham Reiterates Buy on Celcuity, Maintains $23 Price Target

Needham analyst Ryan Koontz reiterates Gilat Satellite Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) with a Buy and maintains $8.5 price target.

GILT

Needham Reiterates Buy on Gilat Satellite Networks, Maintains $8.5 Price Target

<ul>
<li>Aegon today announces a planned new EUR 150 million share buyback program, consistent with its policy to return excess Cash Capital at Holding to shareholders in the absence of value-creating opportunities. Barring unforeseen circumstances, the share buyback program will start at the beginning of January 2025 and is expected to be completed on or before June 30, 2025. The start of this share buyback program will be announced separately in due course.&nbsp;</li>
<li>The new planned EUR 150 million share buyback program will include an amount of about EUR 40 million to meet Aegon's obligations resulting from the share-based compensation plans for senior management. The repurchased shares resulting from these compensation plans will be held as treasury shares until they are allocated to the plan participants. Aegon intends to cancel the remainder of the repurchased shares resulting from the new planned share buyback program, subject to any relevant approval.</li>
</ul>

Aegon Announces €150M Share Buyback Starting January 2025, With €40M For Compensation And The Rest For Cancellation, Pending Approval

Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has filed a lawsuit against the Health Resources and Services Administration (HRSA). The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount offerings to hospitals.
What Happened: As per Eli Lilly&#8217;s official statement on Thursday, the conflict centers on the federal 340B program, which requires drug manufacturers to offer discounts to healthcare providers serving low-income communities. Participation in this program is crucial for drug companies to secure funding from government health insurance programs like Medicare and Medicaid.
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis. However, HRSA, a division of the U.S. Health and Human Services Department, rejected this approach, stating it was inconsistent with the 340B law.
&#8220;HRSA does not have the authority to arbitrarily reject this model, which serves the original goals of the 340B program and improves transparency, efficiency, and program integrity,&#8221; the statement read.
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Why It Matters: The lawsuit comes amid ongoing scrutiny of drug pricing practices. Recently, <a href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price">Doctors Without Borders</a> criticized Eli Lilly and other insulin manufacturers for maintaining high prices, urging them to provide affordable insulin to low- and middle-income countries.
This legal action also <a href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs">follows a similar lawsuit</a> by Johnson &amp; Johnson, which alleged the Health and Human Services Department of blocking its drug rebate plans. The 340B program has been subject to extensive legal challenges, with a U.S. appeals court previously allowing drugmakers to limit the use of outside pharmacies for dispensing under the program.
Meanwhile, Eli Lilly has been in the spotlight for its <a href="https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for-even-at-three-years">Phase 3 trial data</a> of tirzepatide, marketed as Mounjaro and Zepbound. The study showed promising results in reducing the risk of type 2 diabetes in patients with pre-diabetes and obesity, highlighting the company&#8217;s focus on innovative treatments.
Price Action: Eli Lilly was down by 0.28% during pre-market hours on Friday at the time of writing, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41921267/new-jersey-is-making-history-by-offering-medical-cannabis-as-employee-benefit?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">New Jersey Is Making History By Offering Medical Cannabis</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Biotech

Government

Health Care

General

Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program

Needham analyst James Ricchiuti reiterates 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) with a Hold.

Needham Reiterates Hold on 3D Sys

Aegon trading update for third quarter 2024&nbsp;
• EUR 336 million operating capital generation, before holding funding and operating expenses. Full-year 2024 guidance raised to around EUR 1.2 billion, from around EUR 1.1 billion previously&nbsp;
• Capital ratios of the main units remain above their respective operating levels&nbsp;
• Planned new EUR 150 million share buyback program announced; completion expected in the first half of 2025. The program includes neutralization of shares issued for share-based compensation plans&nbsp;
• Cash Capital at Holding of EUR 1.5 billion as of September 30, 2024. Expect to reach mid-point of the target range (EUR 1.0 billion) by the end of 2026&nbsp;
• Completed program to purchase institutionally owned universal life policies. Terminated policies negatively impacted US RBC ratio by 16%-points. Expect 8%-points benefit in 4Q 2024 after equity funding repayment. Operating capital generation benefits from the program, as previously guided&nbsp;
• Strong commercial momentum in Asset Management and UK Workplace platform. US Strategic Assets experience c

Aegon Q3 Business Update: Operating Capital Generation €336M Before Holding Expenses; Raised FY24 Operating Capital Target To ~€1.2B, Up From The Previous Estimate Of €1.1B

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

GOVX

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) with a Buy and maintains $9 price target.

INKT

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) with a Neutral.

STTK

HC Wainwright & Co. Reiterates Neutral on Shattuck Labs

Macro Economic Events

Econ #s

Economics

U.K. Labour Productivity For Q2 0.2% Vs. 0.1% Prior

HC Wainwright &amp; Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and maintains $14 price target.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $14 Price Target

Coca-Cola European Partners plc Ordinary Shares

CCEP

Coca-cola Europacific Partners Says The Financial Conduct Authority Approved Its Transfer Of Listing Category From Equity Shares Category To Equity Shares (Commercial Companies) Category Of Official List

Michael Burry, the hedge fund manager renowned for predicting the 2008 financial crisis, has significantly increased his exposure to Chinese technology companies while simultaneously implementing protective measures against potential downside risks, <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">according to regulatory filings</a>.
What Happened: Burry&#8217;s Scion Asset Management made several notable adjustments to its portfolio during the third quarter, with Chinese companies now representing its largest positions. The firm increased its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) by 29%, making it the fund&#8217;s largest holding valued at over $21 million as of September&#8217;s end.
In a similar move, Scion doubled its position in JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), elevating it to the fund&#8217;s second-largest holding at approximately $20 million. The firm also expanded its stake in Chinese search giant Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) by 67%, bringing the position to $13.2 million.
However, in what appears to be a cautionary strategy, Burry has simultaneously established put options against these same holdings. Put options typically increase in value when the underlying securities decline, suggesting a hedging strategy designed to protect against potential market volatility.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41999238/ross-gerber-blasts-teslas-support-for-ending-ev-tax-credit-as-insanity-amid-reported-policy-shift-under-trump-administration">Long-Time Tesla Bull Rages As Elon Musk Reportedly Backs Trump&#8217;s Plan To Ax $7.5K EV Credit: &#8216;Insanity&#8217;</a>
The timing of these moves coincides with Beijing&#8217;s recent economic stimulus announcements aimed at reinvigorating growth in the world&#8217;s second-largest economy. While Chinese equities initially rallied in September following these signals, gains have moderated as investors await more concrete fiscal measures.
Beyond his Chinese technology focus, Burry has also increased positions in several U.S. companies, including Shift4 Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), American Coastal Insurance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>), and Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
Why It Matters: Burry&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">top three Chinese holdings</a> have posted average gains of nearly 60% over a two-month period, according to market data.
Burry&#8217;s moves are being closely watched by market participants, particularly given his track record. He gained widespread recognition for his prescient bet against mortgage-backed securities before the 2008 global financial crisis, a story later chronicled in Michael Lewis&#8216;s bestseller &#8220;The Big Short&#8221; and its subsequent Oscar-winning film adaptation.
It&#8217;s worth noting that these positions reflect holdings as of Sep. 30, as required by SEC regulations for funds managing over $100 million in assets. Given the 45-day reporting delay and Burry&#8217;s active trading style, current positions may have already changed.
The development comes as other <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">prominent investors adjust their Chinese holdings</a>. Billionaire investor David Tepper&#8217;s Appaloosa Management recently reduced its Alibaba stake by 5%, though the position remains the fund&#8217;s largest holding at 15.75% of its $6.7 billion portfolio.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/content/41999311/jim-cramer-says-these-10-frothy-stocks-are-up-over-200-ytd-including-rocket-lab-palantir-and-carvana">Jim Cramer Says These 10 &#8216;Frothy&#8217; Stocks Are Up Over 200% YTD, Including Rocket Lab, Palantir, And Carvana</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Global

Markets

ACIC

BABA

BIDU

FOUR

'Big Short' Investor Michael Burry Doubles Down On Chinese Tech Stocks While Adding Protective Hedges

NATL

NCR Atleos Inks Five-year Agreement To Provide Atleos' Cashzone Network ATMs In The John Lewis Partnership's Waitrose Supermarkets Across The UK

Warning: GFAI is at high risk of performing badly

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Everyone&rsquo;s current favorite antagonist, Federal Reserve Chair Jerome Powell, might be turning the tide with his latest comment on the economy. In a recent address, He stated, &ldquo;I don&rsquo;t see the &lsquo;stag&rsquo; or the &lsquo;flation&rsquo;,&rdquo; dispelling concerns about a 1970s-like stagflation. Hence, an economic recovery is well within sight, which bodes well for undervalued AI <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>.



<a href="https://investorplace.com/industries/technology/artificial-intelligence/">AI stocks</a> have been panned in recent weeks after taking the stock market to record highs last year. However, few, if any, can take away the AI industry&rsquo;s disruptive long-term potential. As I&rsquo;ve mentioned multiple times in my articles of late, we&rsquo;re still in the early stages of what promises to be a long and illustrious era for AI.



The Magnificent Seven hogged the spotlight last year, overshadowing the impressive strides made by undervalued AI penny stocks. Here are three that impress the most but caution is advised considering the speculative nature of these investments.



<h2>Guardforce AI (GFAI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/ai1600b-300x169.jpg" alt="AI stocks an intelligent robot figure representing ai stocks, investing for the next decade. Artificial Intelligence Stocks"><div>Source: Shutterstock</div></div>Guardforce AI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gfai-stock-quote/">GFAI</a>) is an interesting AI penny stock, which leverages disruptive technology to deliver robust robotics-based security solutions. This unique focus on robotics-based security positions it ahead of its competition and as a frontrunner in the field.



Moreover, its recent quarterly performances show healthy single-digit revenue growth, while comfortably beating analyst estimates. Additionally, its <a href="https://seekingalpha.com/symbol/GFAI/cash-flow-statement">free cash flow balance</a> stands at an impressive $11 million as of last year, 148% higher than the prior-year period.



Furthermore, the firm is moving forward with strategic partnerships and acquisitions to further strengthen its positioning. It recently bought out robot-related business assets from&nbsp;Shenzhen Kewei Robot Technology which could significantly enhance GFAI&rsquo;s Robot-as-a-Service (RaaS) sales and capabilities. Also, its <a href="https://s3.amazonaws.com/b2icontent.irpass.cc/2688/rl120322.pdf">collaboration with Concorde Security&nbsp;</a>in Singapore is another feather in its proverbial cap. Concorde expects GFAI&rsquo;s robotic security solutions to effectively manage visitors while performing routine tasks such as janitorial duties.&nbsp; Despite the positives GFAI stock hasn&rsquo;t struck a chord with investors yet, but offers superb long-term potential.



<h2>Inuvo (INUV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/06/telecommunications1600-300x169.png" alt="Rack Mounted Servers In A Server Room, Server rack audio cable. Severs computer in a rack at the large data center. Fiber Optical connector interface for Cards Equipment DWDM telecommunications. KLR stock"><div>Source: Funtap / Shutterstock.com</div></div>Why spend 30 cents on a gumball when you could pick up Inuvo&nbsp;(NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/inuv-stock-quote/">INUV</a>) stock and chew on even bigger returns?



It wasn&rsquo;t like that for communication services firm Inuvo, though. It traded 99.5% lower than its all-time high price of $60.80. INUV stock has fallen out of favor with investors for a while, having shed more than 50% of its value in the past decade.



However, it ranks among the few firms revitalizing themselves last year through AI-driven initiatives. Inuvo made the rounds last year due to its powerful <a href="https://inuvo.com/intentkey/">AI-based consumer intent recognition platform</a> in IntentKey. &nbsp;



The platform essentially mimics the human brain in associating ideas, emotions, objects, among other things for brands to effectively target the right audience. Moreover, the advertising market is back, adding to the stock&rsquo;s attractiveness.&nbsp; Recent results have shown a healthy uptick in sales growth, while its <a href="https://seekingalpha.com/symbol/INUV/momentum/performance">stock price is up 75%</a> in the past six months.



<h2>Predictive Oncology (POAI)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2018/11/pharmacymsn-300x165.jpg" alt="a hand grabbing a prescription from a shelf full of drugs"><div>Source: Shutterstock</div></div>Predictive Oncology&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/" target="_blank">POAI</a>) is another moonshot AI penny stock play in the pharmaceutical space. It&rsquo;s a company that uses the power of AI to significantly improve outcomes in the drug discovery process. Without getting into the boring specifics, the bottom line is that the firm helps develop incredibly effective medical treatments more efficiently and accurately. Consequently, treatments can become more personalized and effective for a diverse population.



A bet on the company&nbsp;is a bet on the robust growth expected in the AI-led drug discovery market. According to a MarketsandMarkets report, the sector is projected to grow from&nbsp;<a target="_blank" href="https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html#:~:text=The%20size%20of%20global%20AI,40.2%25%20from%202023%20to%202028.">$0.9 billion in 2023 to $4.9 billion by 2028</a>, at a 40.2% CAGR over a five-year period.



Hence, there is a&nbsp;growing trend in the pharma sphere to employ AI in the research and development process, positioning POAI stock for healthy long-term gains.



On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor&rsquo;s of science degree in applied accounting from Oxford Brookes University.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/the-3-most-undervalued-ai-penny-stocks-to-buy-in-may-2024/">The 3 Most Undervalued AI Penny Stocks to Buy in May 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Most Undervalued AI Penny Stocks to Buy in May 2024

Guardforce AI Co (GFAI) has released an update. Guardforce AI Co., Limited has announced a significant expansion in Thailand by securing a 5-year c...

Guardforce AI Expands Cash Center Operations in Thailand

Guardforce AI Co (GFAI) has released an update. Guardforce AI Co., Limited, a company incorporated in the Cayman Islands, has registered an offerin...

Guardforce AI Announces Registered Share Offering

Guardforce AI Co (GFAI) has released an update. Guardforce AI Co., a provider of integrated security and AI solutions, has significantly expanded i...

Guardforce AI Broadens Reach in Asia Pacific Retail

Guardforce AI Co (GFAI) has released an update. Guardforce AI Co., an established provider of integrated security and AI solutions, will be present...

Guardforce AI to Showcase at Global Investment Conference

Guardforce AI Co (GFAI) has released an update. Guardforce AI Co., Limited has announced a new partnership with Outside The Box Capital Inc., in wh...

Guardforce AI Co. Enhances Marketing with Equity Deal

Guardforce AI Co (GFAI) has released an update. Guardforce AI Co., Limited has reported a decrease in total assets to $36.2 million as of June 2024...

Guardforce AI Reports Decreased Assets

Guardforce AI Co (GFAI) has released an update. Guardforce AI Co., Limited has announced the immediate departure of Mr. Kee Yun Kwan from his role ...

Guardforce AI Announces COO Departure

GFAI

INUV

POAI

Opinion

Press Releases

Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?

Events

Guardforce to Present at the Planet MicroCap Showcase: VEGAS 2024 on May 1, 2024

Earnings

Guardforce AI Reports Record Revenue of $36.3 Million for 2023

Guardforce AI Launches AI Robotic Solution 'LinguaBot' Through Strategic Partnership with iApp Technology

Guardforce AI expands in Thailand with new LinguaBot solution as it addresses AI demand

Guardforce AI Secures 5-Year Contract to Operate Consolidated Cash Center in Thailand, Enhancing Comprehensive Service Capabilities Along with AI Solutions for Retail Clients

Comments

Guardforce AI Co

Noticias

Últimas noticias sobre Guardforce AI Co (NASDAQ:GFAI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL